180 Life Sciences Corp. (ATNF) Financial Statements
Industry: Finance Services
In fiscal 2025, 180 Life Sciences reported revenue of $6.5M. Net income was -$450.5M (a -6881.3% net margin), or -$54.32 per diluted share. Operating margin was -3565.8%. Operating activities generated -$26.1M of cash, leaving -$270.3M of free cash flow. At fiscal year end, 180 Life Sciences held $306.3M in total assets against $66.9M in total liabilities, including $8.0M of cash and equivalents.
Open the full interactive 180 Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
180 Life Sciences Key Stats
| Share Price | $4.19 |
|---|---|
| Market Cap | $71.5M |
| 52-Week Range | $1.79 – $21.77 |
| Shares Outstanding | 17.1 million (basic, 2026 Q2) |
180 Life Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $6.5M |
| Operating Income | -$5.6M | -$15.6M | -$17.9M | -$13.5M | -$6.3M | -$233.4M |
| Pre-Tax Income | -$10.9M | -$20.3M | -$39.7M | -$22.3M | -$6.5M | -$443.5M |
| Income Tax | -$20,427 | -$23,204 | -$942,749 | -$2.3M | -$296,024 | $7.0M |
| Net Income | -$10.9M | -$20.3M | -$38.7M | -$19.9M | -$6.2M | -$450.5M |
| Diluted EPS | -$2508.00 | -$2470.00 | -$3524.50 | -$525.90 | -$154.90 | -$54.32 |
180 Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $4.1M | $2.4M | $2.9M | $1.4M |
| Net Income | -$216.7M | -$229.7M | -$76.3M | -$12.8M |
| Diluted EPS | -$16.80 | -$28.13 | -$3.64 | -$0.73 |
180 Life Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | — | — | — | — | $8.0M |
| Current Assets | $4.0M | $11.2M | $8.9M | $3.6M | $5.1M | $13.6M |
| Total Assets | $55.5M | $62.7M | $19.7M | $5.3M | $12.8M | $306.3M |
| Current Liabilities | $21.4M | $19.7M | $5.7M | $5.1M | $3.5M | $40.9M |
| Total Long-Term Debt | $1.1M | $1.9M | $1.3M | $1.1M | $168,075 | $57.7M |
| Total Liabilities | $25.2M | $23.4M | $8.3M | $5.4M | $3.5M | $66.9M |
| Shareholders' Equity | $30.3M | $39.3M | $11.3M | -$127,733 | $9.3M | $239.4M |
180 Life Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.9M | -$19.4M | -$12.1M | -$10.9M | -$1.5M | -$26.1M |
| Cash From Investing | $14.5M | — | — | — | — | -$127.6M |
| Cash From Financing | -$8.6M | $25.4M | $10.9M | $5.9M | $4.0M | $158.2M |
| Free Cash Flow | — | — | — | — | — | -$270.3M |
Figures from 180 Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full 180 Life Sciences financials page for every line item.
180 Life Sciences Company Profile
| Ticker | ATNF |
|---|---|
| Exchange | Nasdaq |
| Industry | Finance Services |
| Headquarters | Palm Beach, Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001690080 |
Frequently Asked Questions
What was 180 Life Sciences' revenue in fiscal 2025?
180 Life Sciences (ATNF) reported revenue of $6.5M for fiscal 2025.
What is 180 Life Sciences' annual revenue history?
180 Life Sciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $6.5M.
What was 180 Life Sciences' net income in fiscal 2025?
180 Life Sciences reported net income of -$450.5M for fiscal 2025.
What was 180 Life Sciences' earnings per share (EPS) in fiscal 2025?
180 Life Sciences' diluted EPS was -$54.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did 180 Life Sciences generate in fiscal 2025?
180 Life Sciences generated -$270.3M of free cash flow in fiscal 2025.
What was 180 Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), 180 Life Sciences reported revenue of $1.4M.
How much debt does 180 Life Sciences have?
180 Life Sciences reported $57.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of 180 Life Sciences are outstanding?
180 Life Sciences reported a weighted average of 17.1 million basic shares outstanding in 2026 Q2.
What is 180 Life Sciences' market cap?
Based on its latest closing price, 180 Life Sciences (ATNF) has a market capitalization of about $71.5M.
When does 180 Life Sciences' fiscal year end?
180 Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is 180 Life Sciences headquartered?
180 Life Sciences lists its business address in Palm Beach, Florida in its SEC filings.